These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26091846)

  • 1. Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2).
    Onoda N; Sugitani I; Higashiyama T; Hara H; Ito K; Kammori M; Sugino K; Suzuki S; Toda K; Yoshida A; Miyauchi A
    BMC Cancer; 2015 Jun; 15():475. PubMed ID: 26091846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
    Sugitani I; Onoda N; Ito KI; Suzuki S
    J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.
    Onoda N; Sugino K; Higashiyama T; Kammori M; Toda K; Ito K; Yoshida A; Suganuma N; Nakashima N; Suzuki S; Tsukahara K; Noguchi H; Koizumi M; Nemoto T; Hara H; Miyauchi A; Sugitani I
    Thyroid; 2016 Sep; 26(9):1293-9. PubMed ID: 27484330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The anaplastic thyroid carcinoma research consortium of Japan].
    Sugitani I
    Nihon Geka Gakkai Zasshi; 2012 Jul; 113(4):368-72. PubMed ID: 22928442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
    Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
    J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
    Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic thyroid carcinoma: a 25-year single-institution experience.
    Mohebati A; Dilorenzo M; Palmer F; Patel SG; Pfister D; Lee N; Tuttle RM; Shaha AR; Shah JP; Ganly I
    Ann Surg Oncol; 2014 May; 21(5):1665-70. PubMed ID: 24554064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
    von Roemeling CA; Copland JA
    Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
    Ladoire S; Rambach L; Quipourt V; Favier L; Ghiringhelli F; Arnould L; Pfitzenmeyer P; Fumoleau P; Coudert B
    Clin Breast Cancer; 2011 Aug; 11(4):235-40. PubMed ID: 21737355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
    Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
    Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data.
    Ursino S; Fiorica F; Stefanelli A; Pedriali M; Colosimo C; Cocuzza P; Mazzotti V; Taibi R; Cartei F; Greco C
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1368-72. PubMed ID: 24867515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathological analysis of anaplastic thyroid carcinoma cases with long-term survival: A report from the Anaplastic Thyroid Carcinoma Research Consortium of Japan.
    Hirokawa M; Sugitani I; Kakudo K; Sakamoto A; Higashiyama T; Sugino K; Toda K; Ogasawara S; Yoshimoto S; Hasegawa Y; Imai T; Onoda N; Orita Y; Kammori M; Fujimori K; Yamada H
    Endocr J; 2016 May; 63(5):441-7. PubMed ID: 26842589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosbretabulin for the treatment of anaplastic thyroid cancer.
    Granata R; Locati LD; Licitra L
    Future Oncol; 2014 Oct; 10(13):2015-21. PubMed ID: 25396774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
    Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
    Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.
    Akaishi J; Sugino K; Kitagawa W; Nagahama M; Kameyama K; Shimizu K; Ito K; Ito K
    Thyroid; 2011 Nov; 21(11):1183-9. PubMed ID: 21936674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.